Kids with IBD and psoriasis may benefit from switching to ustekinumab
NCT ID NCT07529236
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 40 children with Crohn's disease or ulcerative colitis who developed severe psoriasis from anti-TNF drugs and switched to ustekinumab. Researchers will check if their digestive symptoms stay controlled and if their skin improves after 3-6 months. The goal is to see if this switch is a good option for managing both conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ustekinumab
What this could lead to
If successful, this could show that switching to ustekinumab is a safe and effective way to manage both IBD and treatment-related psoriasis in children.
What could go wrong
This is a small, observational study with only 40 children, so results may not apply to everyone. It also does not compare ustekinumab to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nice
RECRUITINGNice, France, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact